Difference between revisions of "Afatinib (Gilotrif)"
Jump to navigation
Jump to search
(clinical trials) |
|||
| Line 1: | Line 1: | ||
| − | + | '''In clinical trials.''' Also known as Tomtovok. | |
==General information== | ==General information== | ||
| Line 7: | Line 7: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert. | ||
| + | |||
| + | ==Clinical trials== | ||
| + | *[http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=114&abstractID=91942 LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations] | ||
| + | *LUX-Lung 2 - Afatinib for EGFR positive lung adenocarcinoma after no more than one previous chemotherapy regimen for advanced disease<ref>Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller VA. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012 May;13(5):539-48. Epub 2012 Mar 26. [http://www.sciencedirect.com/science/article/pii/S1470204512700864 link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/22452895 PubMed]</ref> | ||
| + | *LUX-Lung 1 - Afatinib vs. placebo for lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy<ref>Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, Heo DS, Crino L, Tan EH, Chao TY, Shahidi M, Cong XJ, Lorence RM, Yang JC. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012 May;13(5):528-38. Epub 2012 Mar 26. [http://www.sciencedirect.com/science/article/pii/S1470204512700876 link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/22452896 PubMed]</ref> | ||
==Patient drug information== | ==Patient drug information== | ||
Revision as of 18:27, 26 July 2012
In clinical trials. Also known as Tomtovok.
General information
Class/mechanism: Irreversible tyrosine kinase inhibitor of members of the erbB family, such as EGFR (epidermal growth factor receptor) and HER2 (human epidermal growth factor receptor 2)[1]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.
Clinical trials
- LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations
- LUX-Lung 2 - Afatinib for EGFR positive lung adenocarcinoma after no more than one previous chemotherapy regimen for advanced disease[2]
- LUX-Lung 1 - Afatinib vs. placebo for lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy[3]
Patient drug information
No information available.
References
- ↑ Press release: Boehringer Ingelheim broadens its breast cancer clinical trial program for the investigational compound afatinib
- ↑ Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller VA. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012 May;13(5):539-48. Epub 2012 Mar 26. link to original article PubMed
- ↑ Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, Heo DS, Crino L, Tan EH, Chao TY, Shahidi M, Cong XJ, Lorence RM, Yang JC. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012 May;13(5):528-38. Epub 2012 Mar 26. link to original article PubMed